HFA Icon

Valeant Pharmaceuticals: Ackman Ups Stake, ValueAct Digs In

HFA Padded
Rupert Hargreaves
Published on
Updated on
Sign up for our E-mail List and Get FREE Access to Exclusive Investment E-books and More!

Valeant Pharmaceuticals still has plenty of supporters despite the media storm surrounding the company and its businesses practices.

Last night it emerged that Bill Ackman, one of Valeant’s most staunch supporters, has upped Pershing Square’s stake in Valeant to 9.9% of the company’s outstanding shares — a near 70% increase in Pershing’s holding before recent declines.

Pershing Square Ups Valeant Stake Explained In A Few Charts

Bill Ackman’s Pershing Square is now Valeant Pharmaceuticals’ second largest shareholder

Bill Ackman’s Pershing Square is now Valeant’s second largest shareholder after the Sequoia Fund, which is run by Ruane, Cuniff & Goldfarb. The Sequoia Fund itself has come under fire for its Valeant position. Two of the fund’s five...

HFA Padded

Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway. Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK. Rupert covers everything value investing for Hedge Fund Alpha